Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Diminishing biofilm resistance to antimicrobial nanomaterials through electrolyte screening of electrostatic interactions.

Harper RA, Carpenter GH, Proctor GB, Harvey RD, Gambogi RJ, Geonnotti AR, Hider R, Jones SA.

Colloids Surf B Biointerfaces. 2018 Sep 12;173:392-399. doi: 10.1016/j.colsurfb.2018.09.018. [Epub ahead of print]

PMID:
30317126
2.

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.

Chehab S, Zhang C, Panjic EH, Chen Z, Kaufman JL, Lonial S, Nooka A, Harvey RD.

Cancer. 2018 Oct 10. doi: 10.1002/cncr.31746. [Epub ahead of print]

PMID:
30303526
3.

Design and development of a biorelevant simulated human lung fluid.

Hassoun M, Royall PG, Parry M, Harvey RD, Forbes B.

J Drug Deliv Sci Technol. 2018 Oct;47:485-491. doi: 10.1016/j.jddst.2018.08.006.

4.

Accelerating anticancer drug development - opportunities and trade-offs.

Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL.

Nat Rev Clin Oncol. 2018 Oct 1. doi: 10.1038/s41571-018-0102-3. [Epub ahead of print] Review.

PMID:
30275514
5.

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.

Harvey RD, Aransay NR, Isambert N, Lee JS, Arkenau T, Vansteenkiste J, Dickinson PA, Bui K, Weilert D, So K, Thomas K, Vishwanathan K.

Br J Clin Pharmacol. 2018 Sep 1. doi: 10.1111/bcp.13753. [Epub ahead of print]

PMID:
30171779
6.

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.

Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K.

Clin Pharmacokinet. 2018 Aug 17. doi: 10.1007/s40262-018-0702-1. [Epub ahead of print] Review.

PMID:
30117017
7.

Rationale, Opportunities, and Reality of Biosimilar Medications.

Lyman GH, Zon R, Harvey RD.

N Engl J Med. 2018 Aug 16;379(7):694-695. doi: 10.1056/NEJMc1808348. No abstract available.

8.

Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.

Moore DC, Arnall JR, Harvey RD.

J Oncol Pharm Pract. 2018 Jul 31:1078155218788706. doi: 10.1177/1078155218788706. [Epub ahead of print]

PMID:
30060709
9.

Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.

Owonikoko TK, Busari AK, Kim S, Chen Z, Akintayo A, Lewis C, Carthon BC, Alese OB, El-Rayes BF, Ramalingam SS, Harvey RD.

Oncology. 2018;95(3):138-146. doi: 10.1159/000488763. Epub 2018 Jun 18.

PMID:
29913438
10.

Reply to S.D. Lucio.

Lyman GH, Zon R, Harvey RD, Schilsky RL.

J Clin Oncol. 2018 Jul 10;36(20):2127. doi: 10.1200/JCO.2018.79.1780. Epub 2018 May 30. No abstract available.

PMID:
29847292
11.

A combined FTIR and DSC study on the bilayer-stabilising effect of electrostatic interactions in ion paired lipids.

Schmid M, Wölk C, Giselbrecht J, Chan KLA, Harvey RD.

Colloids Surf B Biointerfaces. 2018 May 17;169:298-304. doi: 10.1016/j.colsurfb.2018.05.031. [Epub ahead of print]

PMID:
29793092
12.

Rationale, Opportunities, and Reality of Biosimilar Medications.

Lyman GH, Zon R, Harvey RD, Schilsky RL.

N Engl J Med. 2018 May 24;378(21):2036-2044. doi: 10.1056/NEJMhle1800125. No abstract available.

PMID:
29791832
13.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2018 May 21. doi: 10.1007/s10637-018-0610-0. [Epub ahead of print]

PMID:
29781056
14.

Compartmentalized cAMP Signaling Associated With Lipid Raft and Non-raft Membrane Domains in Adult Ventricular Myocytes.

Agarwal SR, Gratwohl J, Cozad M, Yang PC, Clancy CE, Harvey RD.

Front Pharmacol. 2018 Apr 23;9:332. doi: 10.3389/fphar.2018.00332. eCollection 2018.

15.

Glycerol Solvates DPPC Headgroups and Localizes in the Interfacial Regions of Model Pulmonary Interfaces Altering Bilayer Structure.

Terakosolphan W, Trick JL, Royall PG, Rogers SE, Lamberti O, Lorenz CD, Forbes B, Harvey RD.

Langmuir. 2018 Jun 12;34(23):6941-6954. doi: 10.1021/acs.langmuir.8b00866. Epub 2018 May 30.

PMID:
29738253
16.

Influence of the Surfactant Structure on Photoluminescent π-Conjugated Polymer Nanoparticles: Interfacial Properties and Protein Binding.

Urbano L, Clifton L, Ku HK, Kendall-Troughton H, Vandera KA, Matarese BFE, Abelha T, Li P, Desai T, Dreiss CA, Barker RD, Green MA, Dailey LA, Harvey RD.

Langmuir. 2018 May 29;34(21):6125-6137. doi: 10.1021/acs.langmuir.8b00561. Epub 2018 May 17.

PMID:
29726688
17.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

PMID:
29590007
18.

American Society of Clinical Oncology Statement: Biosimilars in Oncology.

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL.

J Clin Oncol. 2018 Apr 20;36(12):1260-1265. doi: 10.1200/JCO.2017.77.4893. Epub 2018 Feb 14.

PMID:
29443651
19.

Soft, adhesive (+) alpha tocopherol phosphate planar bilayers that control oral biofilm growth through a substantive antimicrobial effect.

Harper RA, Saleh MM, Carpenter G, Abbate V, Proctor G, Harvey RD, Gambogi RJ, Geonnotti A, Hider R, Jones SA.

Nanomedicine. 2018 Oct;14(7):2307-2316. doi: 10.1016/j.nano.2017.12.024. Epub 2018 Feb 2.

20.

Intranasal Ketamine and Its Potential Role in Cancer-Related Pain.

Singh V, Gillespie TW, Harvey RD.

Pharmacotherapy. 2018 Mar;38(3):390-401. doi: 10.1002/phar.2090. Epub 2018 Feb 23. Review.

PMID:
29396996
21.

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.

Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD.

Br J Clin Pharmacol. 2018 Jun;84(6):1156-1169. doi: 10.1111/bcp.13534. Epub 2018 Mar 23.

PMID:
29381826
22.

cAMP Signaling Compartmentation: Adenylyl Cyclases as Anchors of Dynamic Signaling Complexes.

Johnstone TB, Agarwal SR, Harvey RD, Ostrom RS.

Mol Pharmacol. 2018 Apr;93(4):270-276. doi: 10.1124/mol.117.110825. Epub 2017 Dec 7.

PMID:
29217670
23.

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL.

Br J Cancer. 2017 Nov 21;117(11):1592-1599. doi: 10.1038/bjc.2017.330. Epub 2017 Oct 3.

24.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.

Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L.

J Clin Oncol. 2017 Nov 20;35(33):3753-3759. doi: 10.1200/JCO.2017.74.4102. Epub 2017 Oct 2.

PMID:
28968172
25.

Science of Biosimilars.

Harvey RD.

J Oncol Pract. 2017 Sep;13(9_suppl):17s-23s. doi: 10.1200/JOP.2017.026062. Review.

PMID:
28898589
26.

Comparing the action of HT61 and chlorhexidine on natural and model Staphylococcus aureus membranes.

Hubbard AT, Coates AR, Harvey RD.

J Antibiot (Tokyo). 2017 Oct;70(10):1020-1025. doi: 10.1038/ja.2017.90. Epub 2017 Aug 2.

PMID:
28765589
27.

The influence of mild acidity on lysyl-phosphatidylglycerol biosynthesis and lipid membrane physico-chemical properties in methicillin-resistant Staphylococcus aureus.

Rehal RP, Marbach H, Hubbard ATM, Sacranie AA, Sebastiani F, Fragneto G, Harvey RD.

Chem Phys Lipids. 2017 Aug;206:60-70. doi: 10.1016/j.chemphyslip.2017.06.007. Epub 2017 Jun 23.

PMID:
28648851
28.

Compartmentalized cAMP responses to prostaglandin EP2 receptor activation in human airway smooth muscle cells.

Agarwal SR, Miyashiro K, Latt H, Ostrom RS, Harvey RD.

Br J Pharmacol. 2017 Aug;174(16):2784-2796. doi: 10.1111/bph.13904. Epub 2017 Jul 12.

29.

A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias.

Yang PC, Perissinotti LL, López-Redondo F, Wang Y, DeMarco KR, Jeng MT, Vorobyov I, Harvey RD, Kurokawa J, Noskov SY, Clancy CE.

J Physiol. 2017 Jul 15;595(14):4695-4723. doi: 10.1113/JP273142. Epub 2017 Jun 14.

30.

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K.

Clin Pharmacokinet. 2017 Nov;56(11):1355-1368. doi: 10.1007/s40262-017-0526-4.

31.

Mechanism of Action of a Membrane-Active Quinoline-Based Antimicrobial on Natural and Model Bacterial Membranes.

Hubbard AT, Barker R, Rehal R, Vandera KA, Harvey RD, Coates AR.

Biochemistry. 2017 Feb 28;56(8):1163-1174. doi: 10.1021/acs.biochem.6b01135. Epub 2017 Feb 13.

PMID:
28156093
32.

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Wu B, Lewis LD, Harvey RD, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML.

Clin Pharmacol Ther. 2017 Aug;102(2):313-320. doi: 10.1002/cpt.617. Epub 2017 Jun 9.

PMID:
28074547
33.

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

Beardslee TJ, Harvey RD.

Cancer. 2016 Nov 15;122(22):3424-3427. doi: 10.1002/cncr.30273. Epub 2016 Aug 15. No abstract available.

34.

Preventing and Managing Toxicities of High-Dose Methotrexate.

Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD.

Oncologist. 2016 Dec;21(12):1471-1482. Epub 2016 Aug 5. Review.

35.

Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Mita MM, Nemunaitis J, Grilley-Olson J, El-Rayes B, Bekaii-Saab T, Harvey RD, Marshall J, Zhang X, Strout V.

Target Oncol. 2016 Dec;11(6):807-814.

PMID:
27457707
36.

A Computational Modeling and Simulation Approach to Investigate Mechanisms of Subcellular cAMP Compartmentation.

Yang PC, Boras BW, Jeng MT, Docken SS, Lewis TJ, McCulloch AD, Harvey RD, Clancy CE.

PLoS Comput Biol. 2016 Jul 13;12(7):e1005005. doi: 10.1371/journal.pcbi.1005005. eCollection 2016 Jul.

37.

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.

Gupta N, Hanley MJ, Harvey RD, Badros A, Lipe B, Kukreti V, Berdeja J, Yang H, Hui AM, Qian M, Zhang X, Venkatakrishnan K, Chari A.

Br J Haematol. 2016 Sep;174(5):748-59. doi: 10.1111/bjh.14125. Epub 2016 May 16.

38.

Calcium and Cancer: Of Evil Humors and Innocent Bystanders.

Harvey RD.

J Oncol Pract. 2016 May;12(5):433-4. doi: 10.1200/JOP.2016.012385. No abstract available.

PMID:
27170691
39.

Navigating the Landscape of Molecular Testing and Targeted Treatment of Non-Small Cell Lung Cancer.

Padda SK, Harvey RD.

J Adv Pract Oncol. 2016 Apr;7(3):299-301. Epub 2016 Apr 1. Review. No abstract available.

40.

Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.

Olszanski AJ, Smith DC, Camacho LH, Thompson J, Ramalingam SS, Harvey RD, Campos L, Ferry D, Tang S, Gao L, Safran H.

Oncologist. 2016 Apr;21(4):402-3. doi: 10.1634/theoncologist.2015-0467. Epub 2016 Mar 16.

41.

Mechanisms Restricting Diffusion of Intracellular cAMP.

Agarwal SR, Clancy CE, Harvey RD.

Sci Rep. 2016 Jan 22;6:19577. doi: 10.1038/srep19577.

42.

The influence of rough lipopolysaccharide structure on molecular interactions with mammalian antimicrobial peptides.

Bello G, Bodin A, Lawrence MJ, Barlow D, Mason AJ, Barker RD, Harvey RD.

Biochim Biophys Acta. 2016 Feb;1858(2):197-209. doi: 10.1016/j.bbamem.2015.11.007. Epub 2015 Nov 17.

43.

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.

Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S.

Clin Cancer Res. 2016 Jan 1;22(1):34-43. doi: 10.1158/1078-0432.CCR-15-1237. Epub 2015 Nov 11.

44.

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.

Richardson PG, Harvey RD, Laubach JP, Moreau P, Lonial S, San-Miguel JF.

Expert Rev Clin Pharmacol. 2016;9(1):35-48. doi: 10.1586/17512433.2016.1096773. Epub 2015 Oct 26. Review.

PMID:
26503877
45.

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.

Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD.

Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30.

46.

Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.

Jagirdar N, Harvey RD, Nooka A, Flowers C, Kaufman J, Lonial S, Lechowicz MJ, Langston A, Lipscomb C, Gaylor C, Waller EK.

Transfusion. 2015 Oct;55(10):2351-7. doi: 10.1111/trf.13186. Epub 2015 Sep 2.

PMID:
26331348
47.

Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life.

Baz R, Lin HM, Hui AM, Harvey RD, Colson K, Gallop K, Swinburn P, Laubach J, Berg D, Richardson P.

Support Care Cancer. 2015 Sep;23(9):2789-97. doi: 10.1007/s00520-015-2644-6. Epub 2015 Feb 24.

PMID:
25708126
48.

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.

Owonikoko TK, Ramalingam SS, Miller DL, Force SD, Sica GL, Mendel J, Chen Z, Rogatko A, Tighiouart M, Harvey RD, Kim S, Saba NF, Pickens A, Behera M, Fu RW, Rossi MR, Auffermann WF, Torres WE, Bechara R, Deng X, Sun SY, Fu H, Gal AA, Khuri FR.

Clin Cancer Res. 2015 Apr 15;21(8):1859-68. doi: 10.1158/1078-0432.CCR-14-1998. Epub 2015 Feb 11.

49.

Surface chemistry of photoluminescent F8BT conjugated polymer nanoparticles determines protein corona formation and internalization by phagocytic cells.

Ahmad Khanbeigi R, Abelha TF, Woods A, Rastoin O, Harvey RD, Jones MC, Forbes B, Green MA, Collins H, Dailey LA.

Biomacromolecules. 2015 Mar 9;16(3):733-42. doi: 10.1021/bm501649y. Epub 2015 Jan 30.

PMID:
25590257
50.

Development and testing of a tool to assess patient preferences for phase I clinical trial participation.

Pentz RD, Hendershot KA, Wall L, White TE, Peterson SK, Thomas CB, McCormick J, Green MJ, Lewis C, Farmer ZL, Hlubocky FJ, Dossul T, Dixon MD, Liu Y, Switchenko JM, Salvador C, Owonikoko TK, Harvey RD, Khuri FR.

Psychooncology. 2015 Jul;24(7):835-8. doi: 10.1002/pon.3731. Epub 2014 Dec 19. No abstract available.

Supplemental Content

Loading ...
Support Center